Tau protein study in late-onset psychosis
Part of Mental health clinical trials.
This study looks at brain proteins called tau in people who develop psychosis later in life (after age 60). Researchers want to understand how these proteins relate to symptoms, which may help find better treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 65 to 85 years old.
- You have been diagnosed with a late-onset psychosis (psychosis starting after age 60) or delusional disorder.
- You have a caregiver who can join study visits and answer questions about you.
- You have no memory problems that would suggest mild cognitive impairment or dementia.
- You can hear well enough with or without hearing aids to pass a hearing test.
- You do not have any serious medical conditions like epilepsy, Parkinson's, stroke, or heart disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at “tau” (a brain protein) and brain-signal patterns in people with Alzheimer’s disease who have psychotic symptoms like hallucinations or delusions. It may help researchers understand what’s happening in the brain and how to better target these symptoms.
This study uses a special PET scan to measure tau protein buildup in the brain of people with Parkinson's disease (including those with a LRRK2 gene mutation), Progressive Supranuclear Palsy, or Corticobasal Syndrome. It aims to better understand how tau relates to these conditions.
This study uses a brain scan called PET to look at tau (a brain protein) and how it relates to thinking and memory. It may help researchers understand early brain changes, though it’s mainly for healthy people living near Columbia who have had an amyloid PET scan before.
This Phase 3 study uses a PET/CT scan to measure whether a brain protein called tau (and related disease patterns) builds up in different dementia conditions. The goal is to better match which disorders have which brain changes and how they progress.
This trial studies how tau (a protein linked to Alzheimer’s and related conditions) shows up on a special brain scan called tau PET. It also uses MRI and blood work to understand brain changes and who may be at risk, helping researchers improve future diagnosis.
This study uses a special PET/CT brain scan to look at a protein called tau in people with memory/thinking and movement disorders. The results may help researchers understand how these diseases affect the brain and improve future diagnosis or care.
Hear when a new Late Onset Schizophrenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.